Histone deacetylase 6 inhibition reduces cysts by decreasing cAMP and Ca2+ in knock-out mouse models of polycystic kidney disease

J Biol Chem. 2017 Oct 27;292(43):17897-17908. doi: 10.1074/jbc.M117.803775. Epub 2017 Sep 8.

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is associated with progressive enlargement of multiple renal cysts, often leading to renal failure that cannot be prevented by a current treatment. Two proteins encoded by two genes are associated with ADPKD: PC1 (pkd1), primarily a signaling molecule, and PC2 (pkd2), a Ca2+ channel. Dysregulation of cAMP signaling is central to ADPKD, but the molecular mechanism is unresolved. Here, we studied the role of histone deacetylase 6 (HDAC6) in regulating cyst growth to test the possibility that inhibiting HDAC6 might help manage ADPKD. Chemical inhibition of HDAC6 reduced cyst growth in PC1-knock-out mice. In proximal tubule-derived, PC1-knock-out cells, adenylyl cyclase 6 and 3 (AC6 and -3) are both expressed. AC6 protein expression was higher in cells lacking PC1, compared with control cells containing PC1. Intracellular Ca2+ was higher in PC1-knock-out cells than in control cells. HDAC inhibition caused a drop in intracellular Ca2+ and increased ATP-simulated Ca2+ release. HDAC6 inhibition reduced the release of Ca2+ from the endoplasmic reticulum induced by thapsigargin, an inhibitor of endoplasmic reticulum Ca2+-ATPase. HDAC6 inhibition and treatment of cells with the intracellular Ca2+ chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid tetrakis(acetoxymethyl ester) reduced cAMP levels in PC1-knock-out cells. Finally, the calmodulin inhibitors W-7 and W-13 reduced cAMP levels, and W-7 reduced cyst growth, suggesting that AC3 is involved in cyst growth regulated by HDAC6. We conclude that HDAC6 inhibition reduces cell growth primarily by reducing intracellular cAMP and Ca2+ levels. Our results provide potential therapeutic targets that may be useful as treatments for ADPKD.

Keywords: AMP; calcium; calcium ATPase; calcium channel; calcium intracellular release; calmodulin (CaM); histone deacetylase 6 (HDAC6); histone deacetylase inhibitor (HDAC inhibitor) (HDI).

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Calcium / metabolism*
  • Calcium Chelating Agents / pharmacology
  • Calcium Signaling / drug effects*
  • Calcium Signaling / genetics
  • Cell Line
  • Cyclic AMP / genetics
  • Cyclic AMP / metabolism*
  • Cysts / enzymology*
  • Cysts / genetics
  • Cysts / pathology
  • Disease Models, Animal
  • Histone Deacetylase 6
  • Histone Deacetylase Inhibitors / pharmacokinetics*
  • Histone Deacetylases / genetics
  • Histone Deacetylases / metabolism*
  • Mice
  • Mice, Knockout
  • Mice, Transgenic
  • Polycystic Kidney, Autosomal Dominant / enzymology*
  • Polycystic Kidney, Autosomal Dominant / genetics
  • Polycystic Kidney, Autosomal Dominant / pathology
  • Protein Kinase C / genetics
  • Protein Kinase C / metabolism
  • TRPP Cation Channels / genetics
  • TRPP Cation Channels / metabolism
  • Thapsigargin / pharmacology

Substances

  • Calcium Chelating Agents
  • Histone Deacetylase Inhibitors
  • TRPP Cation Channels
  • polycystic kidney disease 2 protein
  • Thapsigargin
  • Cyclic AMP
  • protein kinase D
  • Protein Kinase C
  • Hdac6 protein, mouse
  • Histone Deacetylase 6
  • Histone Deacetylases
  • Calcium